Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | MicrobiomeTrials← Back to trialsNCT06371417
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-08-19Est. Completion: 2026-06-30
Enrollment target: 144 participants Locations- University of California-Irvine, Orange, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Northwell Health, LLC PRIME, Lake Success, New York, United States
- Hospital for Special Surgery, New York, New York, United States
- Universtity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Amarillo Center for Clinical Research, Amarillo, Texas, United States
- Austin Neuromuscular Center, Austin, Texas, United States
- Nerve and Muscle Center of Texas, Houston, Texas, United States
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- Westmead Hospital, Sydney, New South Wales, Australia
- Campbelltown Public Hospital, Sydney, New South Wales, Australia
- The Alfred Hospital, Melbourne, Victoria, Australia
Other microbiome trials you might be interested in
Antiphospholipid Syndrome (APS)Thrombosis
This is a Phase I, open-label, dose escalation, multicenter study to evaluate the safety, tolerability, preliminary effi…
Beijing, ChinaEst. completion Sep 30, 2027
Antiphospholipid Syndrome (APS)
This is a phase II, single-centre, open-label pilot study evaluating the safety and tolerability of anifrolumab in adult…
Athens, GreeceEst. completion Jun 2028
Box Hill Hospital, Melbourne, Victoria, AustraliaAKH - Medizinische Universitaet Wien, Abteilung fuer Klinische Pharmakologie, Vienna, AustriaDiagnostic Consultation Center CONVEX EOOD, Sofia, Sofia City Province, Bulgaria"SHATHD" EAD Sofia, Sofia, Sofia City Province, BulgariaUMHAT "Prof. Dr. St. Kirkovich", AD, Stara Zagora, Stara Zagora Province, BulgariaUniversity of Alberta Hospital - Department of Anesthesiology and Pain Medicine, Edmonton, Alberta, CanadaUniversity of Alberta Hospital - Dermatology, Edmonton, Alberta, CanadaThe Royal Institution for the Advancement of Learning/McGill University, Montreal, Quebec, CanadaCentre de Rhumatologie de l'Est du Quebec, Rimouski, Quebec, CanadaDIEX Recherche Sherbrooke Inc., Sherbrooke, Quebec, CanadaClinical Hospital Center "Sestre Milosrdnice", Zagreb, City of Zagreb, CroatiaUniversity hospital centre Zagreb, Zagreb, City of Zagreb, CroatiaSpecialty Hospital Medico, Rijeka, Primorje-Gorski Kotar County, CroatiaSanatorium Profesora Arenbergera, Prague, Prague, CzechiaHopital Lapeyronie,Service d'Immuno Rhumatologie, Montpellier, Occitanie, FranceAP-HP Hôpital Universitaire Pitié Salpêtrière, Paris, Île-de-France Region, FranceUniversitaetsklinikum Tuebingen, Tübingen, Baden-Wurttemberg, GermanyUniversitaetsklinikum Erlangen, Erlangen, Bavaria, GermanyUniversitaetsklinikum Carl Gustav Carus TU Dresden, Klinik und Poliklinik f. Dermatologie, Sachsen, Bundesländer, GermanyUniversitaetsmedizin Goettingen, Göttingen, Göttingen District, GermanyUniversitaetsklinikum Schleswig Holstein - Campus Luebeck, Klinik f Dermatologie, Allergologie u Venerologie, Lübeck, Schleswig-Holstein, GermanySzegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Csongrád-Csanád County, HungarySemmelweis Egyetem, Budapest, HungaryIRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST, Meldola, Forlì-Cesena Province, ItalyIstituto Clinico Humanitas, Milan, Milan Province, ItalyOspedale San Giovanni Bosco, Torino, Turin Province, ItalyHokkaido University Hospital, Sapporo, Hokkaido, JapanTohoku University Hospital, Sendai, Miyagi, JapanKindai University Hospital, Sayama, Osaka, JapanOsaka University Hospital, Suita, Osaka, JapanHamamatsu University Hospital, Hamamatsu, Shizuoka, JapanNational Center of Neurology and Psychiatry, Kodaira, Tokyo, JapanToho University Omori Medical Center, Ōta-ku, Tokyo, JapanOkayama University Hospital, Okayama, JapanUniversity Medical Centre Groningen UMCG, Groningen, Groningen Province, NetherlandsUMC Utrecht, Utrecht, Utrecht Province, NetherlandsSorlandet sykehus Kristiansand, Kristiansand, Agder County, NorwayStavanger Universitetssjukehus, Stavanger, Rogaland County, NorwayInstitute Reumatologii I'm. Eleonory Reicher, Warsaw, Masovian Voivodeship, PolandCentro Clinico Academico Braga, Braga, Braga District, PortugalCentro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia, Porto District, PortugalCentrul Medical Monza SRL, Bucharest, Bucharest Municipality, RomaniaOncology Institute Prof. Dr. Ion Chiricuta I.O.C.N., Cluj-Napoca, Cluj, RomaniaClinica Universidad de Navarra, Pamplona, Community of Madrid & Navarre, SpainHospital Universitario Ramon y Cajal, Servicio de Reumatologia, Madrid, Madrid, SpainHospital Universitario 12 de October, Madrid, Madrid, SpainHospital Universitari Vall d'Hebron, Internal Medicine Dept., Barcelona, Province of Barcelona and Catalonia, SpainHospital Universitario Reina Sofia, Córdoba, Province Of Córdoba, SpainHospital Universitario Virgen del Rocio, Seville, Province Of Seville, SpainHospital Universitari i Politecnic La Fe, Valencia, Valencia, SpainNational Taiwan University Hospital, Taipei, TaiwanTaichung Veterans General Hospital, Taipei, TaiwanDr. Abdurrahman Yurtaslan Oncology Teaching and Research Hospital, Ankara, Ankara, Turkey (Türkiye)Istanbul University Istanbul Medical Faculty, Istanbul, Istanbul, Turkey (Türkiye)Recruiting
Antiphospholipid Syndrome
Antiphospholipid antibody syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are prot…
Durham, United StatesEst. completion Mar 2029